Kidney transplants: a smarter way to dose Anti-Infectives?
NCT ID NCT07765615
First seen Aug 14, 2026 · Last updated Aug 14, 2026
Summary
This study explores whether tracking rapid changes in kidney function right after a kidney transplant can help doctors choose the right dose of anti-infective drugs. Currently, dosing relies on static tests that may not reflect the fast shifts in kidney performance during the first days after surgery. By analyzing biomarkers and drug levels, researchers aim to build a model that supports personalized dosing, potentially improving safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Precision dosing strategies for anti-infective agents, guided by dynamic kidney function markers
- What this could lead to
- If successful, this could lead to safer, more effective anti-infective dosing for kidney transplant patients, reducing complications and improving recovery.
- What could go wrong
- This is a small, early-stage study focused on modeling and validation, so results may not apply broadly. Individual responses to drugs can vary, and the approach needs further testing before routine use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSPLANT RECIPIENT (KIDNEY) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.